Last reviewed · How we verify

SMOFlipid + Omegaven — Competitive Intelligence Brief

SMOFlipid + Omegaven (SMOFlipid + Omegaven) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipid emulsion / Parenteral nutrition supplement. Area: Critical Care / Nutritional Support.

marketed Lipid emulsion / Parenteral nutrition supplement Critical Care / Nutritional Support Small molecule Live · refreshed every 30 min

Target snapshot

SMOFlipid + Omegaven (SMOFlipid + Omegaven) — General University Hospital, Prague. SMOFlipid + Omegaven is a lipid emulsion combination that provides essential fatty acids and nutritional support for parenteral nutrition, with Omegaven supplying omega-3 fatty acids to modulate inflammatory responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SMOFlipid + Omegaven TARGET SMOFlipid + Omegaven General University Hospital, Prague marketed Lipid emulsion / Parenteral nutrition supplement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipid emulsion / Parenteral nutrition supplement class)

  1. General University Hospital, Prague · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SMOFlipid + Omegaven — Competitive Intelligence Brief. https://druglandscape.com/ci/smoflipid-omegaven. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: